Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Milczarek, G. J.
Right arrow Articles by Bowden, G.T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Milczarek, G. J.
Right arrow Articles by Bowden, G.T.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 20, No. 6, 1043-1048, June 1999
© 1999 Oxford University Press


Carcinogenesis

Okadaic acid mediates p53 hyperphosphorylation and growth arrest in cells with wild-type p53 but increases aberrant mitoses in cells with non-functional p53

Gavin J. Milczarek1, Weixing Chen2, Ashok Gupta2, Jesse D. Martinez2 and G.Tim Bowden1,2,3

1 Department of Molecular and Cellular Biology and
2 Department of Radiation Oncology, Arizona Cancer Center, The University of Arizona, 1501 North Cambell Avenue, Tucson, AZ 85724, USA

The protein phosphatase inhibitor and tumor promoting agent okadaic acid (OA), has been shown previously to induce hyperphosphorylation of p53 protein, which in turn correlated with increased transactivation or apoptotic function. However, how the tumor promotion effects of OA relate to p53 tumor supressor function (or dysfunction) remain unclear. Rat embryonic fibroblasts harboring a temperature-sensitive mouse p53 transgene were treated with 50 nM doses of OA. At the wild-type permissive temperature this treatment resulted in: (i) the hyperphosphorylation of sites within tryptic peptides of the transactivation domain of p53; (ii) an increase in p53 affinity for a p21waf1 promotor oligonucleotide; (iii) an increase in cellular steady state levels of p21waf1 message; (iv) a G2/M cell cycle blockage in addition to the G1/S arrest previously associated with p53; and (v) no increased incidence of apoptosis. On the other hand, OA treatment at the mutated p53 permissive temperature resulted in a relatively high incidence of aberrant mitosis with no upregulation of p21waf1 message. These results suggest that while wild-type p53 blocks the proliferative effects of OA through p21waf1-mediated growth arrest, cells with non-functional p53 cannot arrest and suffer relatively high levels of OA-mediated aberrant mitoses.

Abbreviations: DMSO, dimethyl sulfoxide; OA, okadaic acid.

3 To whom correspondence should be addressed Email: bowdenlab{at}azcc.arizona.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Toxicol PatholHome page
S. P. Clark, T. P. Ryan, G. H. Searfoss, M. A. Davis, and S. B. Hooser
Chronic Microcystin Exposure Induces Hepatocyte Proliferation with Increased Expression of Mitotic and Cyclin-associated Genes in P53-deficient Mice
Toxicol Pathol, February 1, 2008; 36(2): 190 - 203.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
D.J. Messner, P. Ao, A.B. Jagdale, and A.L. Boynton
Abbreviated cell cycle progression induced by the serine/threonine protein phosphatase inhibitor okadaic acid at concentrations that promote neoplastic transformation
Carcinogenesis, August 1, 2001; 22(8): 1163 - 1172.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.